

## TENEZA

**For the use of a Registered Medical Practitioner or a Hospital or a Laboratory Only**

Abbreviated Prescribing information for TENEZA [Teneligliptin Hydrochloride 20 mg tablets]  
[Please refer the complete prescribing information available at [www.torrentpharma.com](http://www.torrentpharma.com)]

### PHARMACOLOGICAL PROPERTIES:

**MECHANISM OF ACTION:** The glucagon-like peptide-1 (GLP-1) is secreted from alimentary canal in response to meal that promotes insulin secretion from pancreas and regulates blood sugar post meal by controlling glucagon secretion. Teneligliptin exhibits a hypoglycemic effect by controlling the decomposition of GLP-1 by inhibiting dipeptidyl peptidase-4 (DPP-4) activity and thereby increasing blood concentration of active GLP-1.

**INDICATIONS:** For the treatment of type 2 Diabetes Mellitus as a monotherapy adjunct to diet and exercise.

**DOSAGE AND ADMINISTRATION:** The usual adult dose for oral use is 20 mg of Teneligliptin once daily. In case of insufficient effect, dosage can be increased to 40mg once time daily while closely monitoring the clinical progress.

**CONTRAINDICATION:** Hypersensitivity to the drug or any of its components. Severe ketosis, diabetic coma or pre-coma and also for immediate remedy in type 1 Diabetes (since a prompt correction of hyperglycaemias is required) with infusion and insulin. Severe trauma before and after surgery and when the blood glucose level is controlled with insulin injection.

**WARNINGS & PRECAUTIONS:** Careful administration recommended in patient with severe hepatic dysfunction, heart failure, sulfonyl urea medication or Insulin formulations risk of hypoglycemia, Hypoglycemia may occur in patients with, Adrenal insufficiency, Malnutrition, starved state, irregular dietary intake, insufficient dietary intake or hyposthenia, Vigorous muscular movement, Patient with excessive alcohol consumption, Patient with history of abdominal surgery or intestinal obstruction, QT prolongation may occur in patients having arrhythmia, Acute pancreatitis has been reported. when coadministered with sulfonylurea or insulin formulation, there is a possibility of higher risk of hypoglycemia. During administration of Teneligliptin, regularly check the blood sugar; check the effect of the drug. there is a possibility that adverse reactions, such as QT prolongation, might occur.

**DRUG INTERACTIONS:** Sulfonylurea, Fast-acting insulin secretagogue,  $\alpha$ -glucosidase inhibitor, Biguanides drugs, Thiazolidine drug, GLP-1 analogue preparation, SGLT2 inhibitor insulin preparation,  $\beta$ -blocking agents, Salicylic acid drugs, Monoamine oxidase inhibitor, Adrenaline, Adrenocortical hormone, Thyroid hormone, Quinidine Sulphate Hydrate, Procainamide Hydrochloride, Amiodarone, Sotalol Hydrochloride.

**ADVERSE REACTIONS:** Hypoglycemia, Intestinal Obstruction, Liver dysfunction, Interstitial pneumonia, Constipation, abdominal swelling, abdominal discomfort, nausea, stomach ache, flatulence, stomatitis, gastric polyp, colon polyp, duodenal ulcer, reflux esophagitis, diarrhea, anorexia, increased amylase, increased lipase, acute pancreatitis, Albuminuria, positive ketone body in urine,

### MARKETED BY:



Torrent Pharmaceuticals Limited.

**IN/TENEZA 20mg/Dec-19/01/ABPI**

(Additional information is available on request)